key: cord-0709082-lcaagdus authors: van Haren, Frank M. P.; Page, Clive; Laffey, John G.; Artigas, Antonio; Camprubi-Rimblas, Marta; Nunes, Quentin; Smith, Roger; Shute, Janis; Carroll, Mary; Tree, Julia; Carroll, Miles; Singh, Dave; Wilkinson, Tom; Dixon, Barry title: Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence date: 2020-07-22 journal: Crit Care DOI: 10.1186/s13054-020-03148-2 sha: c4a5caeab2870e701efa03d0f7b2cb5b920d0a94 doc_id: 709082 cord_uid: lcaagdus Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and warrants urgent investigation of its therapeutic potential, for COVID-19-induced acute respiratory distress syndrome (ARDS). COVID-19 ARDS displays the typical features of diffuse alveolar damage with extensive pulmonary coagulation activation resulting in fibrin deposition in the microvasculature and formation of hyaline membranes in the air sacs. Patients infected with SARS-CoV-2 who manifest severe disease have high levels of inflammatory cytokines in plasma and bronchoalveolar lavage fluid and significant coagulopathy. There is a strong association between the extent of the coagulopathy and poor clinical outcomes. The anti-coagulant actions of nebulised UFH limit fibrin deposition and microvascular thrombosis. Trials in patients with acute lung injury and related conditions found inhaled UFH reduced pulmonary dead space, coagulation activation, microvascular thrombosis and clinical deterioration, resulting in increased time free of ventilatory support. In addition, UFH has anti-inflammatory, mucolytic and anti-viral properties and, specifically, has been shown to inactivate the SARS-CoV-2 virus and prevent its entry into mammalian cells, thereby inhibiting pulmonary infection by SARS-CoV-2. Furthermore, clinical studies have shown that inhaled UFH safely improves outcomes in other inflammatory respiratory diseases and also acts as an effective mucolytic in sputum-producing respiratory patients. UFH is widely available and inexpensive, which may make this treatment also accessible for low- and middle-income countries. These potentially important therapeutic properties of nebulised UFH underline the need for expedited large-scale clinical trials to test its potential to reduce mortality in COVID-19 patients. In December 2019, a novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) emerged in China and has since spread globally. A large proportion of patients admitted to hospital for coronavirus disease 2019 (COVID- 19) develop acute respiratory distress syndrome (ARDS) criteria according to the Berlin definition [1] [2] [3] . ARDS is an acute inflammatory lung injury, associated with increased pulmonary vascular permeability, increased lung weight and loss of aerated lung tissue, affecting 23% of mechanically ventilated critically ill patients. The hospital mortality of ARDS is estimated between 35 and 46% depending on ARDS severity [4, 5] . However, the death rate in COVID- 19 patients with ARDS appears to be higher, up to 66% [2] . It has been suggested that COVID-19 pneumonia-associated ARDS is a specific disease or perhaps a specific phenotype of ARDS, whose distinctive features are severe hypoxaemia initially associated with relatively well-preserved lung mechanics [6, 7] . A possible explanation for such severe hypoxaemia occurring in compliant lungs is the loss of lung perfusion regulation and hypoxic vasoconstriction. In addition, COVID-19 ARDS patients have higher plasma markers of coagulation, such as D-dimers, increased prothrombin time and a lower platelet count [2, [8] [9] [10] [11] [12] . Endothelial dysfunction and microvascular thrombosis could therefore also explain the specific pulmonary findings in severe COVID-19-high dead space and impaired oxygenation in the absence of significant decrease in pulmonary compliance. Post-mortem studies and lung biopsies of SARS-CoV-2 patients with ARDS indeed demonstrated pulmonary fibrin deposition with hyaline membranes in the alveolar spaces and extensive pulmonary microvascular thrombi [13] [14] [15] . Pulmonary disease severity is also related to an aggressive host inflammatory response to SARS-CoV-2 infection, with release of an uncontrolled cytokine storm inflicting damage to other organs including the cardiac, hepatic and renal systems [16] . In this focused review, we present the biological and scientific rationale for the use of nebulised UFH for COVID-19 pneumonia and ARDS in hospitalised patients and make a call for an urgent, global approach to the investigation of its therapeutic potential for this devastating condition. The pathophysiology of COVID-19 associated ARDS is summarised in Fig. 1a and is characterised by diffuse alveolar damage, hyperinflammation, coagulopathy, DNA neutrophil extracellular traps (NETS), hyaline membranes and microvascular thrombosis. SARS-CoV-2 binds to angiotensin-converting enzyme-2 (ACE-2) to gain cellular entry. ACE-2 is widely expressed -19) . Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensinconverting enzyme 2 (ACE-2) primarily on type II alveolar cells. After endocytosis of the viral complex, surface ACE-2 is downregulated, resulting in unopposed angiotensin II accumulation. SARS-CoV-2 further causes lung injury through activation of residential macrophages, lymphocyte apoptosis and neutrophils. The macrophages produce cytokines and chemokines, resulting in a cytokine storm. Inflammatory exudate rich in plasma-borne coagulation factors enters the alveolar space, followed by expression of tissue factor by alveolar epithelial cells and macrophages and the formation of fibrin and the hyaline membrane. Neutrophils in the alveoli cause formation of NETs, composed of extracellular DNA, cytotoxic histones and neutrophil elastase, which cause further lung injury. COVID-19 also induces microvascular endothelial damage leading to increased permeability, expression of tissue factor with coagulation activation and thrombus formation. b Proposed effects of inhaled nebulised unfractionated heparin (UFH) in COVID-19 lung injury. UFH prevents SARS-CoV-2 from binding to ACE-2 and from entering the alveolar cells. UFH reduces formation of the hyaline membrane and microvascular thrombosis, counteracts the hyperinflammation and the formation of NETs, increases NO release with vasodilation and also has mucolytic properties. NETs, neutrophil extracellular traps; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ACE-2, angiotensin-converting enzyme 2; COVID-19, coronavirus disease 2019. Permission was granted by © Beth Croce, Bioperspective.com to reuse this figure van Haren et al. Critical Care in the lungs, predominantly on alveolar type II epithelial cells, but also on bronchial epithelial cells and on arterial and venous endothelial cells [17, 18] . ACE-2 hijacking prevents angiotensin II degradation. Angiotensin II signals through the type 1 angiotensin receptor, causing vasoconstriction and lung injury, including endothelial injury leading to tissue factor expression and coagulation cascade activation [19] . Widespread endothelial inflammation and apoptosis leading to endothelial dysfunction in multiple organs are associated with direct viral infection of endothelial cells in COVID-19, as well as immune-mediated responses to infection of pulmonary alveolar cells, and a pro-coagulant state [20] . Patients with SARS-CoV-2 who manifest severe disease, including ARDS, multi-organ failure, and death, have higher plasma and BALF levels of inflammatory cytokines ('cytokine storm'); higher plasma markers of coagulation, such as D-dimers; and increased prothrombin time and a lower platelet count [2, [8] [9] [10] [11] [21] [22] [23] ]. An aggressive dysfunctional inflammatory response following pyroptosis of virus-infected cells is strongly implicated in damage to the lungs [16] . For example, plasma concentrations of a range of pro-inflammatory cytokines were higher in both ICU patients and non-ICU patients infected with SARS-CoV-2 than in healthy adults, and some of these agents were also higher in ICU patients than non-ICU patients [9] . Furthermore, elevated plasma IL-6 was reported to be a predictor of fatality, suggesting that mortality might be driven by virally induced hyperinflammation [21, 22] . The expression of a large number of cytokines is also elevated in BALF samples from COVID-19 patients compared to control [23] . Finally, intravascular DNA neutrophil extracellular traps (NETs) have been reported in COVID-19 patients, where they may contribute to cytokine release, coagulopathy and respiratory failure [24, 25] . COVID-19 is associated with the development of ARDS displaying the typical features of diffuse alveolar damage [26] [27] [28] [29] [30] . The hallmark histological feature of ARDS is a fibrin mesh in the air sacs, known as a hyaline membrane, on which leucocytes attach and manifest the inflammatory responses that result in diffuse alveolar damage. Hyaline membrane formation is a consistent and early manifestation of the inflammatory response in ARDS [27, [30] [31] [32] [33] . Hyaline membrane formation results from entry into the alveolar space of inflammatory exudate that is rich in plasma-borne coagulation factors. The subsequent expression of tissue factor by alveolar epithelial cells and macrophages triggers the conversion of these coagulation factors to fibrin and the formation of the hyaline membrane [34] . In pro-inflammatory conditions, alveolar epithelial cells and macrophages also express plasminogen activator inhibitor-1, which prevents the removal of this membrane through endogenous fibrinolysis [32, 35] . Pulmonary coagulation is evident in increased markers of thrombin generation, soluble tissue factor and factor VIIa activity found in bronchoalveolar lavage fluid (BALF) from ARDS patients, together with an increased release of plasminogen activator inhibitor-1 [36] . Hyaline membrane formation may contribute to lung injury through a number of mechanisms. The hyaline membrane forms a physical barrier thereby limiting the diffusion of gases. Alveolar compliance and the action of surfactant are also limited by fibrin formation in the alveoli contributing to atelectasis, and finally, the laying down of a fibrin matrix may promote subsequent lung fibrosis [32, 37] . Fibrin accumulation in pulmonary capillaries and venules, which leads to microvascular thrombosis, is an early feature of ARDS and the extent of this fibrin accumulation correlates with the severity of lung injury [38] [39] [40] [41] . In response to inflammatory cytokines, the pulmonary capillary beds, venules and arterioles express tissue factor on endothelial cells and this triggers the conversion of plasma coagulation factors to fibrin [42] . Cytokine activation of NETosis and the presence of intravascular NETs are further associated with the initiation of thrombosis in arteries and veins, and NETs circulating at high levels in COVID-19 can trigger microembolic occlusion of small blood vessels in the lungs, heart and kidneys [24, 25] . Extensive microvascular thrombosis has been demonstrated in histological studies of ARDS [39, 40] . Angiographic studies showed the extent of microvascular obstruction correlated with the severity of respiratory failure and with mortality [38, 39] . Microvascular thrombosis increases lung dead space and the increase in dead space or its bedside surrogate ventilatory ratio was shown to be an independent marker of mortality in ARDS [43, 44] . Microvascular thrombosis also causes increased pulmonary vascular resistance, which may result in right heart failure [45] . There is a strong association between the extent of the coagulopathy and poor clinical outcomes. In a case series of 183 COVID-19 patients, those who died had markedly elevated D-dimers, elevated fibrin degradation products, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission, often meeting criteria for disseminated intravascular coagulation [46] . Similar coagulation abnormalities were described in other case series and elevated D-dimer levels were associated with clinical outcomes [2, 47, 48] . In a Dutch case series of 184 COVID-19 positive patients, all of which received pharmacological thromboprophylaxis, the cumulative incidence of a composite outcome comprised of symptomatic pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction, or systemic arterial embolism was 49%. The majority of thromboembolic events were PE (87%) [49] . Another recent case series showed that COVID-19 ARDS patients developed significantly more thrombotic complications than non-COVID-19 ARDS patients, mainly PE [12] . Excessive sputum production is a feature of approximately 30% of COVID-19 patients and the bronchi become filled with desquamated epithelial cells, mucus and thick mucus plugs [9, 50, 51] . Diapedesis of neutrophils into the alveolar space is proposed to be a source of excess NETs, composed of extracellular DNA and bound basic proteins including cytotoxic histones and neutrophil elastase, which are involved in both the generation of NETs and damage to pulmonary tissue [25] . Such NETs may further impair gas exchange and facilitate secondary infections. Intra-alveolar NETS are a feature of pneumonia-associated ARDS [52] and are likely to be present in the airways of COVID-19 patients with ARDS. The effects of nebulised UFH in COVID-19 are summarised in Fig. 1b . Nebulised UFH has anti-viral, anticoagulant, anti-inflammatory and mucolytic effects. Heparin is a member of a family of glycosaminoglycan molecules that include heparan sulphate, chondroitin sulphate, keratan sulphate and hyaluronic acid. These molecules are expressed throughout the body, with diverse biological roles, and are usually associated with respiratory and endothelial cell surfaces, basement membrane and extracellular matrices [53] . In humans, heparin is produced solely by mast cells and is stored in granules, where it makes up 30% of the dry weight of mast cell granules [54] . There is evidence that heparin plays a role in host defence. Firstly, mast cells are mostly located along blood vessels and are particularly associated with capillaries and post-capillary venules [55] . Secondly, organs exposed to the external environment, such as the lungs and gut contain a large proportion of the body's mast cells [56] . Thirdly, heparin is conserved across a variety of different species, some of which do not have a blood coagulation system like ours (e.g. molluscs), suggesting heparin has significant biological roles unrelated to coagulation [57] . A large number of bacterial and viral pathogens depend upon interactions with proteoglycan molecules such as heparan sulphate, which is expressed on a range of human tissue surfaces, for adhesion and invasion of host tissues [53] . Several studies found heparin competes with heparan sulphate for bacterial and viral adhesion and may therefore limit pathogen invasion [58, 59] . For example, heparin limits adhesion of Pseudomonas aeruginosa, Burkholderia cenocepacia, Burkholderia pseudomallei, Legionella pneumophila, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, respiratory syncytial virus and influenza A [60] [61] [62] [63] [64] . Human and animal studies suggest these actions may reduce the development of pneumonia and bacteraemia [58, 65] . Previous studies demonstrated that UFH prevented SARS-associated coronavirus and other enveloped viruses such as human immunodeficiency virus and herpes simplex virus, from attaching to and invading mammalian cells [66] [67] [68] [69] [70] [71] [72] . A recent study demonstrated that the SARS-CoV-2 Spike S1 protein receptor-binding domain attaches to UFH and undergoes conformational change that may prevent it from binding ACE-2 as a result [73] . Importantly, the binding of heparin to the receptorbinding domain of the SARS-CoV-2 Spike S1 protein is orders of magnitude stronger for full-chain length heparin than low-+molecular weight heparins (LMWHs) [74] . This anti-viral effect of heparin has recently been confirmed in initial studies performed by Public Health England where an UFH preparation produced a concentration-dependent inhibition of SARS-CoV-2 infection of Vero E6 cells that was more active than LMWH, further suggesting that UFH may prevent invasion of pulmonary epithelium and vascular endothelium (M Carroll and J Tree, personal communication from Public Health England). The high concentration of SARS-Cov2 in the upper airways of COVID-19 patients and the above anti-viral properties of heparin makes the nebulised route of administration a unique and possibly effective treatment for COVID-19. Heparin also has other pharmacological actions of potential benefit including inhibition of inflammatory cytokines implicated in COVID-19 and the inhibition of inflammatory cell recruitment into tissues via blocking many of the key adhesion molecules expressed on vascular endothelium, improvement in lung function and increased nitric oxide release [60, [75] [76] [77] [78] . Heparin has been shown to reduce the expression of proinflammatory mediators in human alveolar macrophages injured by lipopolysaccharide and to decrease the NF-kB pathway in alveolar cells [79] . Furthermore, nebulised heparin decreases pro-inflammatory cytokines in lung tissue and the expression of NF-kB and TGF-β effectors in alveolar macrophages [79, 80] . Heparin, through multiple actions including inhibition of adhesion molecules and heparanase activity, has also been shown to reduce the infiltration of inflammatory cells into a range of tissues, including the lung, activities that are independent of its anti-coagulant properties [78] . Additionally, heparin is known to have important inhibitory effects on the complement cascade that has also been implicated in the vascular injury associated with COVID-19 [78] . In pre-clinical animal models, UFH was a more effective anti-inflammatory agent than LMWHs, which may be an important additional pharmacological property of this drug in the context of the hyperinflammatory state associated with COVID-19 [78, 81] . Overall, the multiple pharmacological properties of UFH may be important in the context of treating the hyperinflammatory state associated with COVID-19, particularly in the absence of clear evidence of the efficacy of other anti-inflammatory therapies [82] . Heparin's anti-coagulant properties have been used in clinical practice to limit systemic fibrin deposition since 1935 [83] . Heparin inhibits coagulation activation through a range of mechanisms, including catalysing the action of antithrombin, promoting tissue factor pathway inhibitor expression, reducing tissue factor expression and increasing endothelial expression of heparan sulphate, and through release of tissue plasminogen activator by the endothelium. Nebulised UFH targets pulmonary fibrin deposition and inflammation, and local administration to the lungs allows higher dosages and increases local efficacy, reduces the risk of systemic bleeding and is more effective than intravenous administration [84, 85] . Importantly, previous studies have shown that following nebulisation, UFH does not enter the systemic circulation significantly which means it can be used in addition to systemic therapeutic or prophylactic anti-coagulation without concerns of furthering systemic anti-coagulation. The use of nebulised UFH in other respiratory settings was not associated with local side effects in the lung including bleeding [85] [86] [87] [88] [89] . Mucus obstruction of the airways is compounded by the presence of DNA NETs in inflammatory lung diseases such as cystic fibrosis (CF), asthma, COPD and ARDS [90] . DNA contributes to sputum elasticity and reduced cough clearance, and in CF sputum, heparin disaggregated DNA/actin bundles and activated endogenous DNase to reduce sputum elasticity [91] . When DNA NETS are broken down, the potential for the release of cytotoxic histones, neutrophil elastase and IL-8 encrypted by the DNA is mitigated by the ability of heparin to neutralise these basic proteins [90] . Independently of the presence of DNA NETs, electrostatic mucin interactions and viscosity are increased by a low pH in airway surface liquid, as seen in cystic fibrosis (CF), asthma, COPD and ARDS and these effects are also reversed by heparin [92, 93] . The mucolytic properties of heparin have been utilised in the treatment of CF patients with no safety issues and in particular inhaled nebulised UFH has been used safely in patients who are also receiving system anti-coagulation [94] . Animal studies of nebulised UFH in different acute lung injury models have consistently shown a positive effect on pulmonary coagulation, inflammation and oxygenation (Table 1) . Small human studies indicate that nebulised heparin limits pulmonary fibrin deposition, attenuates progression of acute lung injury and hastens recovery (Table 2) [95, 96] . In smoke inhalation-related lung injury, pre-clinical and clinical studies have suggested that administration of inhaled anti-coagulants improves oxygenation, reduces lung injury severity and improves survival without altering systemic markers of clotting and anti-coagulation [97] . Early-phase trials in patients with acute lung injury and related conditions found that nebulised heparin reduced pulmonary dead space, coagulation activation, microvascular thrombosis and deterioration in the Murray Lung Injury Score and increased time free of ventilatory support (Table 2 ) [98] [99] [100] [101] [102] . A multi-centre randomised double-blind placebo-controlled trial of nebulised heparin in 256 patients with or at risk of developing ARDS, investigated whether UFH accelerated recovery and has been completed (B Dixon personal communication, submitted for publication). Published data suggest that patients with SARS-CoV-2 treated with systemic UFH or LMWH had better clinical outcomes. For example, a non-randomised study found patients with sepsis-induced coagulopathy and D-dimer levels that were greater than 6-fold the upper limit of normal, were more likely to survive if administered heparin or LMWH [11] . In another observational study in 2773 patients hospitalised with COVID-19, mechanically ventilated patients who received systemic anticoagulation during their hospital course had a lower hospital mortality (adjusted HR of 0.86 per day, 95% confidence interval 0.82-0.89, p < 0.001) [103] . This difference was not seen in all COVID-19 patients, suggesting that the beneficial effects may be more pronounced in patients with severe disease. There are currently no published studies of nebulised heparin in COVID-19 patients, but there are several in preparation or being conducted (Table 2 ). In the UK, a study of nebulised UFH has been started under the national ACCORD programme (ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients, EudraCT number 2020-001736-95). This study is investigating the effects of nebulised UFH administered 4 times daily in hospitalised patients testing positive for SARS-CoV-2, but before patients require ICU admission, on top of standard of care (Singh et al., There is an urgent need for more large-scale clinical trials to test whether nebulised UFH improves mortality in COVID-19 patients. Ideally, these studies should be Severe COVID-19 is characterised by diffuse alveolar damage, hyperinflammation, coagulopathy, DNA neutrophil extracellular traps (NETS) and microvascular thrombosis. There is a strong scientific and biological basis to test the use of nebulised UFH as a therapy for COVID-19 pneumonia and ARDS. UFH prevents SARS-CoV-2 from binding to ACE-2 and infecting cells and has relevant anti-coagulant, anti-inflammatory and mucolytic effects. Because of these multiple modes of action, inhaled UFH may offer clinical benefit across the time course of the disease. As an anti-viral, delivered via inhalation to the upper airways, the major point of entry of the virus, UHF may prevent infection and be a prophylactic treatment. If administered via nebulisation at the development of symptoms, its multiple properties may attenuate disease progression. As the disease progresses, UFH's anti-inflammatory and anti-coagulant properties may be used to treat COVID-19-associated ARDS. In the pneumonic phase of COVID-19, which is typified by excess production of mucus, nebulised UFH's known mucolytic effect can be used to aid recovery. UFH is an inexpensive drug and widely available and its use as a potentially effective treatment for COVID-19 may have important humanitarian and economic implications especially for low-and middle-income countries. The potential therapeutic properties underline the need for expedited large-scale clinical trials of nebulised UFH to test its potential to reduce mortality in COVID-19 patients. Authors' contributions FvH drafted the manuscript. All authors contributed equally to revision and finalisation of the manuscript. The authors read and approved the final manuscript. No funding was obtained for this work. The datasets used for the current manuscript are available from the corresponding author on reasonable request. Ethics approval and consent to participate Not applicable. Not applicable. FvH, CP, JL, QN, RS, BD, JT and MC have nothing to disclose. TW is Chief Investigator of the ACCORD COVID Research Programme. AA and MCR report grants from Grifols, outside the submitted work. JS is the Scientific Director of Ockham Biotech Ltd., a company that owns patents around the use of inhaled heparin. DS reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, personal fees from GlaxoSmithKline, personal fees from Glenmark, personal fees from Gossamerbio, personal fees from Menarini, personal fees from Mundipharma, personal fees from Novartis, personal fees from Peptinnovate, personal fees from Pfizer, personal fees from Pulmatrix, personal fees from Theravance and personal fees from Verona, outside the submitted work. Author details 1 Baseline characteristics and outcomes of 1591 patients Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease Acute respiratory distress syndrome: the Berlin definition Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries Acute respiratory distress syndrome COVID-19 pneumonia: different respiratory treatments for different phenotypes? Management of COVID-19 respiratory distress Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19 Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 A pathological report of three COVID-19 cases by minimal invasive autopsies The trinity of COVID-19: immunity, inflammation and intervention Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Endothelial cell infection and endotheliitis in COVID-19 Hlh Across Speciality Collaboration UK. COVID-19: consider cytokine storm syndromes and immunosuppression Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Neutrophil extracellular traps in COVID-19 Targeting potential drivers of COVID-19: Neutrophil extracellular traps Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 Pathological findings of COVID-19 associated with acute respiratory distress syndrome Clinicopathologic and immunohistochemical findings from autopsy of patient with COVID-19 The acute respiratory distress syndrome Coagulation, fibrinolysis, and fibrin deposition in acute lung injury Unique structural features that influence neutrophil emigration into the lung The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets? Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome Surfactant alteration and replacement in acute respiratory distress syndrome Early bedside detection of pulmonary vascular occlusion during acute respiratory failure The pulmonary vascular lesions of the adult respiratory distress syndrome Pathophysiology of the respiratory distress syndrome The role of microvascular thrombosis in sepsis Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome Physiologic analysis and clinical performance of the Ventilatory ratio in acute respiratory distress syndrome Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: possible association with antifibrinolytic therapy Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Laboratory abnormalities in patients with COVID-2019 infection Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Diagnosis and treatment protocol for novel coronavirus pneumonia. National Health Commission & State Administration of Traditional Chinese Medicine on Clinical and pathological characteristics of 2019 novel coronavirus disease (COVID-19): a systematic review Neutrophil extracellular traps are elevated in patients with pneumonia-related acute respiratory distress syndrome Microbial adherence to and invasion through proteoglycans The anti-inflammatory action of heparin: heparin as an antagonist to histamine, bradykinin and prostaglandin E1 The distribution of mast cells in the human area postrema New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates? Braz Oligosaccharides interfere with the establishment and progression of experimental pneumococcal pneumonia The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection Common oligosaccharide moieties inhibit the adherence of typical and atypical respiratory pathogens Binding of heparan sulfate to Staphylococcus aureus Pseudomonas aeruginosa adherence to human basement membrane collagen in vitro Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans Coronaviridae and SARS-associated coronavirus strain HSR1 Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120 The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry Heparin-induced vasodilation in human hand veins Preventing bronchoconstriction in exerciseinduced asthma with inhaled heparin Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents The non-anticoagulant promise of heparin and its mimetics Role of heparin in pulmonary cell populations in an in-vitro model of acute lung injury Nebulized heparin attenuates pulmonary coagulopathy and inflammation through alveolar macrophages in a rat model of acute lung injury Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China Gordon Murray: heparin, hemodialysis and hubris Nebulized anticoagulants for acute lung injury -a systematic review of preclinical and clinical investigations Anticoagulant therapy in acute respiratory distress syndrome Inhalational use of antithrombotics in humans: review of the literature Anti-inflammatory effects of heparin and its derivatives: a systematic review Pharmacology of heparin and related drugs Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study Neutrophil extracellular traps in pulmonary diseases: too much of a good thing Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis Acid stress in the pathology of asthma Acidic pH increases airway surface liquid viscosity in cystic fibrosis Inhaled heparin in cystic fibrosis Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies Nebulized heparin for patients under mechanical ventilation: an individual patient data meta-analysis Inhaled anticoagulation regimens for the treatment of smoke inhalation-associated acute lung injury: a systematic review Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury Elevated pulmonary dead space and coagulation abnormalities suggest lung microvascular thrombosis in patients undergoing cardiac surgery Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial A trial of nebulised heparin to limit lung injury following cardiac surgery Nebulised Heparin for Lung Injury -Clinical Protocol V1: St.Vincent's Hospital Melbourne Australia Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation, in a model of experimental lung injury Nebulized anticoagulants limit coagulopathy but not inflammation in Pseudomonas aeruginosa-induced pneumonia in rats Postexposure aerosolized heparin reduces lung injury in chlorine-exposed mice Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep Effects of heparin and lisofylline on pulmonary function after smoke inhalation injury in an ovine model Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation Combined anticoagulants ameliorate acute lung injury in sheep after burn and smoke inhalation Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome Effects of nebulized antithrombin and heparin on inflammatory and coagulation alterations in an acute lung injury model in rats A phase 1 trial of nebulised heparin in acute lung injury Is inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients?: the IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcystine [correction of acetylcystine] therapy Use of inhaled heparin/N-acetylcystine in inhalation injury: does it help? Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury Safety and potential anticoagulant effects of nebulised heparin in burns patients with inhalational injury at Singapore General Hospital Burns Centre Does a nebulized heparin/Nacetylcysteine protocol improve outcomes in adult smoke inhalation? Outcomes following the use of nebulized heparin for inhalation injury (HIHI study) HEPBURN -investigating the efficacy and safety of nebulized heparin versus placebo in burn patients with inhalation trauma: study protocol for a multi-center randomized controlled trial Can nebulised heparin reduce time to extubation in SARS CoV 2 the CHARTER Study protocol Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations The authors wish to acknowledge Ms. Beth Croce, medical illustrator, for designing the figure for this manuscript.